Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack L Arbiser

Showing results (11-20 of 214) with videos related to

Pageof 22
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinomaJack L Arbiser
Blood|September 15, 2012
Zebrafish lead the way in control of vascular permeabilityJack L Arbiser
The Journal of Investigative Dermatology|May 14, 2011
Fumarate esters as angiogenesis inhibitors: key to action in psoriasis?Jack L Arbiser
Blood|June 5, 2010
EC-specific chemotaxis receptor: a double-edged swordJack L Arbiser
Journal of the American Academy of Dermatology|July 21, 2009
Gentian violet is safeJack L Arbiser
JAMA|December 14, 2016
Factors Influencing Prescription Drug Costs in the United StatesJack L Arbiser
The Journal of Investigative Dermatology|January 8, 2004
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase)Jack L Arbiser
Blood|May 19, 2012
NHERF-2 silences the silencersJack L Arbiser
The Journal of Clinical Investigation|October 3, 2007
Why targeted therapy hasn't worked in advanced cancerJack L Arbiser
JAMA Dermatology|February 19, 2015
Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the FutureJack L Arbiser
Pageof 22

Showing results (11-20 of 214) with videos related to

Sort By:
Pageof 22
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinomaJack L Arbiser
Blood|September 15, 2012
Zebrafish lead the way in control of vascular permeabilityJack L Arbiser
The Journal of Investigative Dermatology|May 14, 2011
Fumarate esters as angiogenesis inhibitors: key to action in psoriasis?Jack L Arbiser
Blood|June 5, 2010
EC-specific chemotaxis receptor: a double-edged swordJack L Arbiser
Journal of the American Academy of Dermatology|July 21, 2009
Gentian violet is safeJack L Arbiser
JAMA|December 14, 2016
Factors Influencing Prescription Drug Costs in the United StatesJack L Arbiser
The Journal of Investigative Dermatology|January 8, 2004
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase)Jack L Arbiser
Blood|May 19, 2012
NHERF-2 silences the silencersJack L Arbiser
The Journal of Clinical Investigation|October 3, 2007
Why targeted therapy hasn't worked in advanced cancerJack L Arbiser
JAMA Dermatology|February 19, 2015
Efficacy of Rapamycin in Tuberous Sclerosis-Associated Hypopigmented Macules: Back to the FutureJack L Arbiser
Pageof 22